Membrane transporter proteins may influence the sensitivity of cancer cells to anticancer drugs that can be recognized as substrates. The purpose of this study was to identify proteins that play a key role in the drug sensitivity of stomach and breast cancer cell lines by measuring the absolute protein expression levels of multiple transporters and other membrane proteins and examining their correlation to drug sensitivity. Absolute protein expression levels of 90 membrane proteins were examined by quantitative targeted absolute proteomics using liquid chromatography-linked tandem mass spectrometry. Among them, 11 and 14 membrane proteins, including transporters, were present in quantifiable amounts in membrane fraction of stomach cancer and breast cancer cell lines, respectively. In stomach cancer cell lines, the protein expression level of multidrug resistance-associated protein 1 (MRP1) was inversely correlated with etoposide sensitivity. MK571, an MRP inhibitor, increased both the cell-to-medium ratio of etoposide and the etoposide sensitivity of MRP1-expressing stomach cancer cell lines. In breast cancer cell lines, the protein expression level of reduced folate carrier 1 (RFC1) was directly correlated with methotrexate (MTX) sensitivity. Initial uptake rate and steady-state cell-to-medium ratio of [ 3 H]MTX were correlated with both RFC1 expression level and MTX sensitivity. These results suggest that MRP1 modulates the etoposide sensitivity of stomach cancer cell lines and RFC1 modulates the MTX sensitivity of breast cancer cell lines. Our results indicate that absolute quantification of multiple membrane proteins could be a useful strategy for identification of candidate proteins involved in drug sensitivity.
Introduction
Membrane transporters play an important role in determining the sensitivity of cells to various anticancer drugs by mediating transport of drugs across the plasma membrane. ATP-binding cassette (ABC) transporter proteins, including multidrug resistance protein 1 (MDR1), the multidrug resistance-associated protein (MRP) family, and breast cancer resistance protein (BCRP), are involved in multidrug resistance by mediating efflux of anticancer drugs, based on their broad specificity of substrate recognition (Szakacs et al., 2006) . Solute carrier (SLC) transporter proteins also play roles in anticancer drug sensitivity. Equilibrative nucleoside transporter 1 (ENT1) mRNA was found to be downregulated in cell lines resistant to cytarabine, a nucleoside analog anticancer drug (Takagaki et al., 2004) . Downregulation of L-type amino acid transporter 1 (LAT1) mRNA was also reported to be involved in resistance to melphalan (Kuhne et al., 2009 ). These findings suggest that identification of key transporter(s) for each anticancer drug is important to understand the molecular mechanisms of anticancer drug resistance and to allow selection of effective drugs for cancer chemotherapy.
The membrane transporter family consists of 48 ABC transporters and 378 SLC transporters. As drug transport often involves multiple transporters in cancer cells, it is important to identify the transporters that determine drug sensitivity. An "-omics" strategy would be one way to identify the responsible transporters, for example, using genomics to compare mRNA expression of transporters. Genome-wide association studies by O'Brien et al. (2008) demonstrated that overexpression of ABCC3 mRNA in breast cancer cell lines is associated with reduced sensitivity to paclitaxel. However, we recently showed that protein expression of 12 transporters in plasma membrane fraction showed little or no correlation to mRNA expression in human livers from 17 donors (Ohtsuki et al., 2012) . This clearly indicated the necessity to focus on protein expression for identifying responsible transporters.
However, it is difficult to quantitatively evaluate protein expression of transporters by means of standard proteomics techniques due to their low expression levels and problems with two-dimensional polyacrylamide gel electrophoresis analysis of membrane proteins. Recently, we have reported simultaneous quantification of multiple proteins by selected reaction monitoring/multiple reaction monitoring (SRM/ MRM) on the basis of liquid chromatography-linked tandem mass spectrometry (LC-MS-MS) for quantitative targeted absolute proteomics (QTAP) (Kamiie et al., 2008) . In contrast to standard proteomics, which seeks to identify proteins as comprehensively as possible, QTAP enabled us to quantify the absolute expression levels of target proteins, including transporters, with increased sensitivity. We have already employed this method to quantify 22 transporters in plasma membrane fraction of human liver and 16 transporters in whole-cell lysate of human brain microvessels (Uchida et al., 2011; Ohtsuki et al., 2012) . Thus, this method should be suitable to compare protein expression levels of transporters in plasma membrane fraction of cancer cells to identify key transporters associated with drug sensitivity.
In the present study, we used QTAP to analyze protein expression of transporters in stomach and breast cancer cell lines in panels of human cancer cell lines (JFCR-39 and JFCR-45) (Yamori, 2003; Nakatsu et al., 2005) , since large differences in drug sensitivity have been reported in these two groups of cancer cell lines. The transporters associated with drug sensitivity were identified by comparing protein expression and drug sensitivity data. Furthermore, the roles of the identified transporters were confirmed by means of cellular uptake and viability studies.
Materials and Methods
Reagents. [39,59,7- 3 H]Methotrexate disodium salt ([ 3 H]MTX; 27.7 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). Ammonium salts of 4-amino-10-methylpteroyldiglutamic acid (MTX-Glu 2 ), 4-amino-10-methylpteroyltriglutamic acid (MTXGlu 3 ), 4-amino-10-methylpteroyltetraglutamic acid (MTX-Glu 4 ), 4-amino-10-methylpteroylpentaglutamic acid (MTX-Glu 5 ), 4-amino-10-methylpteroylhexaglutamic acid (MTX-Glu 6 ), and 4-amino-10-methylpteroylheptaglutamic acid (MTX-Glu 7 ) were purchased from Schircks Laboratories (Jona, Switzerland). All peptides listed in Supplementary Table 1 were synthesized by Thermo Fisher Scientific (Sedantrabe, Germany). Membrane vesicles prepared from MRP5-transfected and parental vector-transfected human embryonic kidney 293 cells were purchased from SOLVO Biotechnology (Budapest, Hungary). All other reagents were commercial products of analytical grade.
Cell Culture. Six human stomach cancer cell lines (St-4, MKN45, MKN1, MKN28, MKN7, and MKN74) and five human breast cancer cell lines (MCF-7, HBC-4, BSY-1, HBC-5, and MDA-MB-231) in a panel of human cancer cell lines (JFCR-39) (Yamori, 2003) were seeded on noncoated tissue culture dishes (BD Biosciences, Bedford, MA) and cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) containing 5% inactivated fetal bovine serum, penicillin (70 mg/ml), and streptomycin (100 mg/ml) at 37°C with an atmosphere of 5% CO 2 in air.
Preparation of Membrane Fraction. The cells (1.0 Â 10 7 cells) were suspended in buffer containing 250 mM sucrose, 10 mM TrisHCl (pH 7.4), and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and lysed by nitrogen cavitation at 450 psi for 15 minutes at 4°C. Lysed cells were centrifuged at 10,000g for 10 minutes at 4°C, and the supernatants were collected. They were centrifuged at 100,000g for 60 minutes at 4°C. The resulting pellet was suspended in 250 mM sucrose and 10 mM Tris-HCl (pH 7.4) and stored as membrane fraction. Protein concentrations were measured by the Lowry method using the DC protein assay reagent (Bio-Rad, Hercules, CA) with bovine serum albumin as a standard. Average recovered amount of membrane proteins from the 11 cell lines was 516 mg protein/1.0 Â 10 7 cells (247-863 mg protein/1.0 Â 10 7 cells). Protein Quantification by Multiplexed SRM/MRM Analysis with LC-MS-MS. The absolute amounts of membrane proteins and metabolic enzymes of MTX were determined by using a multiplexed SRM/MRM method, as described previously (Kamiie et al., 2008) . Membrane fraction or whole-cell lysate (at least 50 mg protein) was suspended in 0.5 M Tris-HCl (pH 8.5), 7 M guanidine hydrochloride, and 10 mM EDTA, and the proteins were S-carbamoylmethylated. The alkylated proteins were precipitated with a mixture of methanol and chloroform. The precipitates were dissolved in 6 M urea, diluted with 100 mM Tris-HCl (pH 8.5), and digested with sequence-grade modified trypsin (Promega, Madison, WI) at an enzyme/substrate ratio of 1:100 at 37°C for 16 hours. The tryptic digests were mixed with stable isotope-labeled peptide mixture as internal standard peptides. The tryptic digests were acidified with formic acid and then centrifuged at 15,000 rpm for 5 minutes at 4°C. The supernatants were injected into the high-performance liquid chromatography (HPLC) system (Agilent 1100 system; Agilent Technologies, Santa Clara, CA), which was connected to an ESI-triple quadrupole mass spectrometer (API5000; AB Sciex, Foster City, CA). HPLC was performed with C18 columns (ZORBAX SB-C18, 0.5 mm internal diameter Â 150 mm, 5-mm particles; Agilent Technologies). Linear gradients of 1-50% acetonitrile in 0.1% formic acid were applied to elute the peptides at a flow rate of 50 ml/min for 50 minutes. The mass spectrometer was set up to run an SRM/MRM experiment for peptide detection, using a dwell time of 10 milliseconds per SRM/MRM transition. The ion counts in the chromatograms were determined by using the quantitation procedures in Analyst software version 1.5 (AB Sciex).
In the SRM/MRM analysis, each peptide for a target protein was monitored with four kinds of SRM/MRM transitions specific for that peptide. The quantitative value was calculated from the peak area ratio of analyte and stable isotope-labeled peptide in each SRM/MRM transition. Unless otherwise mentioned, at least three of four SRM/ MRM transitions were required to be measurable for a proteotypic peptide to be judged as confirmed and for a quantitative value to be assigned. The value of quantification limit of each protein (femtomoles per microgram of protein) was determined as described previously (Kawakami et al., 2011) .
[ noncoated 24-well plates (Corning, Corning, NY) . After a predetermined interval, cells were washed with ice-cold uptake buffer to terminate the uptake and solubilized. Radioactivity was measured in a liquid scintillation counter (LS6500; Beckman Coulter, Fullerton, CA), and the protein content was determined by the Lowry method using the DC protein assay reagent (Bio-Rad) with bovine serum albumin as a standard.
Etoposide and MTX Uptake Study with SRM/MRM Analysis by LC-MS-MS. Three human stomach cancer cell lines (St-4, MKN45, and MKN1) for etoposide uptake and two human breast cancer cell lines (HBC-4 and HBC-5) for MTX uptake were seeded on noncoated 24-well plates (Corning) or noncoated 12-well plates (Corning) and cultured for 48 hours. The cells were washed with uptake buffer (122 mM NaCl, 25 mM NaHCO 3 , 10 mM D-glucose, 3 mM KCl, 1.4 mM CaCl 2 , 1.2 mM MgSO 4 ·7H 2 O, 0.4 mM K 2 PO 4 , and 10 mM HEPES [pH 7.4]), and the uptake study was initiated at 37°C by applying 1 ml RPMI 1640 medium containing 1 mM etoposide or 200 nM MTX. In the etoposide uptake study, 50 mM MK571 was used as an MRP inhibitor. MK571 was reported to inhibit MRP1-mediated transport of leukotriene C 4 and oxidized glutathione, MRP1 substrates, with a Ki value of 0.6 mM (Leier et al., 1994 (Leier et al., , 1996 . After a predetermined interval, cells were washed with ice-cold uptake buffer to terminate the uptake and solubilized with 0.02 M NaOH or buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, and 1.5 mM MgCl 2 . An equal volume of 0.1% formic acid in acetonitrile was added to remove proteins. These samples were acidified with formic acid and then centrifuged at 15,000 rpm for 5 minutes at 4°C. The supernatants were dried by centrifugation under vacuum, solubilized by adding 0.1% formic acid in water, and then centrifuged at 15,000 rpm for 5 minutes at 4°C. The supernatants were subjected to LC-MS-MS analysis. The conditions of LC-MS-MS analysis are given in Supplementary Table 2 .
Steady-state cell-to-medium (C/M ss , measured as microliters of drug per milligram of protein) ratio was calculated as the ratio of intracellular drug amount per cellular protein amount to drug concentration in the medium, and is also described by eq. 1 in terms of permeability clearance: 
With the assumption that PS inf Â V cell is constant, 1/(C/M ss ratio) 2 1/(C/M ss ratio MK571 ) is proportional to PS eff,MK sensitive . The derivation of eq. 1 and 2 is shown in detail in Supplementary Information 1.
Vesicular Uptake Study of Gemcitabine and MTX with SRM/MRM Analysis by Ultra-Performance Liquid Chromatography (UPLC)-MS-MS. The protein amount of membrane vesicles was determined by the Lowry method using the DC protein assay reagent (Bio-Rad) with bovine serum albumin as a standard. Uptake of gemcitabine and MTX by membrane vesicles was determined by the rapid filtration method, as described previously (Uchida et al., 2007) . Briefly, vesicular uptake was done in uptake medium (250 mM sucrose, 10 mM Tris-HCl, 10 mM MgCl 2 , 4 mM ATP, 10 mM phosphocreatine, and 100 mg/ml creatine phosphokinase [pH 7.4]) containing 100 mM gemcitabine or 10 mM MTX (a known substrate of MRP5). The reactions were carried out at 37°C for 10 minutes (for gemcitabine) or 3 minutes (for MTX) and stopped by the addition of ice-cold stop solution (250 mM sucrose, 10 mM Tris-HCl, and 100 mM NaCl [pH 7.4]). The samples were passed through 0.22-mm Durapore membrane filters (Millipore, Bedford, MA) under vacuum. The filters were then washed three times with ice-cold stop solution and extracted with methanol at room temperature for 1 hour. The extracts were concentrated by centrifugation under vacuum. Then 0.1% formic acid in water was added to the concentrated extracts. This sample was subjected to UPLC-MS-MS analysis. The conditions of UPLC-MS-MS analysis are given in Supplementary  Table 2 . Uptake amount of gemcitabine or MTX was measured by UPLC-MS-MS and expressed as vesicle-to-medium ratio (ml/mg protein).
Cytotoxicity Assay. The cytotoxicity was assessed by colorimetric assay using a Cell Counting Kit (Dojindo, Kumamoto, Japan). The cells were seeded on 96-well plates (Nunc, Roskilde, Denmark) in RPMI 1640 medium. After 24 hours, cells were incubated with several concentrations of etoposide (0.1-100 mM) and 50 mM MK571 (MRP inhibitor) for 72 hours, and then the cell viability was determined according to the manufacturer's instructions. Absorbance was measured at 450 nm with a microplate reader (Model 680; Bio-Rad). The IC 50 was estimated by plotting the rate of cell viability versus the drug concentration.
SDS-PAGE and In-Gel Digestion. Whole-cell lysates of two human breast cancer cell lines (HBC-4 and HBC-5) were mixed with sample buffer, incubated at 37°C for 1 hour, and loaded onto 12% SDS-PAGE gels. Proteins were visualized by Coomassie blue staining. The gel bands that contained FPGS protein (expected molecular weight, 65 kDa) were cut out and minced into small pieces (approximately 1.0 mm 2 ). These gel pieces were washed with 500 ml of 50 mM NH 4 HCO 3 in 50% methanol for 15 minutes and centrifuged. Then, 500 ml of 50 mM NH 4 HCO 3 in 50% acetonitrile was added to the gel pieces and centrifuged. This procedure was repeated until no visible Coomassie blue stain remained. Then, 100 ml of acetonitrile was added and the mixture was centrifuged. The remaining gel pieces were reduced by the addition of 10 mM dithiothreitol in 6 M guanidine hydrochloride/50 mM NH 4 HCO 3 and incubated for 1 hour at room temperature. Acetonitrile (300 ml) was added, and the mixture was centrifuged. The gel pieces were then dried and alkylated at room temperature in the dark for 45 minutes by the addition of 50 mM iodoacetamide in 6 M guanidine hydrochloride/50 mM NH 4 HCO 3 . After removal of the liquid, a solution containing equal volumes of 10% acetic acid and 100% methanol was added to the gel pieces, and the sample tubes were shaken for 30 minutes. This procedure was repeated up to three times. Then, 300 ml of 50 mM NH 4 HCO 3 was added to the gel pieces and the sample tubes were shaken for 15 minutes. After removal of the liquid, 300 ml of acetonitrile was again added to the gel pieces. The sample tubes were shaken for 15 minutes, and then the gel pieces were completely dried in a speed vacuum evaporator for 10 minutes. Trypsin solution (sequence-grade modified trypsin) was added to the gel pieces and incubated at 37°C for 16 hours. The gel pieces were extracted with 0.1% formic acid in 66% acetonitrile by sonication for 10 minutes. The supernatant was stored, and this procedure was repeated up to two times. The remaining gel pieces were further extracted with acetonitrile for 15 minutes. The supernatant was combined and concentrated to approximately 50 ml. The concentrated solution (trypsin-digested peptides) was mixed with stable isotope-labeled peptide mixture as internal standard peptides. The tryptic digests were acidified with formic acid and then centrifuged at 15,000 rpm for 5 minutes at 4°C. The samples were subjected to LC-MS-MS analysis.
Results

Protein Expression Levels of Membrane Proteins in
Human Stomach and Breast Cancer Cell Lines. The expression amounts of 90 membrane proteins, i.e., 34 ABC transporter proteins, 53 SLC transporter proteins, 2 membrane marker proteins (Na 1 /K 1 ATPase and g-GTP), and 1 other membrane molecule (RLIP76, or 76-kDa Ral-interacting protein), were quantified in membrane fraction of six human stomach cancer cell lines and five human breast cancer cell lines by means of QTAP. Eleven membrane proteins (MRP1, GLUT1, 4F2hc, LAT1, MCT1, RFC1, ENT1, ATA1, PCFT, Na 1 /K 1 ATPase, and g-GTP) were detected in the human stomach cancer cell lines (Table 1) . These 11 proteins, together with MRP5, BCRP, and OATP3A1, were detected in the human breast cancer cell lines (Table 2) . GLUT1, 4F2hc, and Na 1 /K 1 ATPase were detected in all 11 cell lines, whereas BCRP expression was detected only in HBC-5 human breast cancer cell line. The other 76 membrane proteins, including MDR1, were all under the limit of quantification in all of the cell lines (Table 3) .
Correlation of MRP1 Protein Expression Level to Chemosensitivity of Human Stomach Cancer Cell Lines. MRP1 has been reported to transport various anticancer drugs, such as vincristine, doxorubicin, epirubicin, and methotrexate (Zeng et al., 2001; Nunoya et al., 2003; Garrido et al., 2011) , and it was detected in three out of six stomach cancer cell lines, but in only one out of five breast cancer cell lines. Among the stomach cancer cell lines, a .16.2-fold difference was observed in the expression level of MRP1, which was the second-largest difference after that of glucose transporter GLUT1 expression (19.3-fold difference) ( Table 1) .
Among the three stomach cancer cell lines expressing MRP1 (St-4, MKN45, and MKN1), the protein expression levels of MRP1 in membrane fraction inversely correlated with sensitivity (|log 10 GI 50 |) to etoposide (r 5 20.994), vincristine (r 5 20.994), epirubicin (r 5 20.986), vinblastine (r 5 20.964), and doxorubicin (r 5 20.952) (Fig. 1) . |log 10 GI 50 | values were obtained from a database of chemosensitivities of a panel of human cancer cell lines (Nakatsu et al., 2005) . High GLUT1 protein expression (.149 fmol/mg protein of membrane fraction) was detected in the three stomach cancer cell lines in which MRP1 was not detected (MKN28, MKN7, and MKN74), whereas the MRP1-expressing cell lines showed lower levels of GLUT1 protein expression (14.8-55.0 fmol/mg protein of membrane fraction) ( Table 1) .
Involvement of MRP1 in Etoposide Sensitivity of Human Stomach Cancer Cell Lines. Among the anticancer drugs shown in Fig. 1 , etoposide has been used for treatment of stomach cancer (Morant, 2001; Lage, 2003) . The involvement of MRP1 in etoposide sensitivity was examined by cytotoxicity assay using the three MRP1-expressing stomach cancer cell lines (St-4, MKN45, and MKN1). In the presence of 50 mM MK571, used for an MRP inhibitor, the IC 50 value of etoposide was decreased in all three cell lines ( Table 4 ). The decreases of the IC 50 values in the high-MRP1-expressing cell lines (St-4 and MKN45) were greater than that in the lower-MRP1-expressing cell line (MKN1).
To examine whether MRP1 protein expression level influences the intracellular amount of etoposide, the C/M ratio of etoposide under a steady-state condition was measured in the presence or absence of MK571. In the presence of 50 mM MK571, the C/M ratio of etoposide was increased in all three stomach cancer cell lines ( Fig. 2A) . In addition, the values of 1/(C/M ss ratio) 2 1/(C/M ss ratio MK571 ), which reflect MK571-sensitive efflux clearance of etoposide, as described in Materials and Methods, correlated well with the protein expression levels of MRP1 (r 5 0.998) (Fig. 2B) .
Correlation of Protein Expression Levels of Membrane Proteins to Anticancer Drug Sensitivity in Human Breast Cancer Cell Lines. The database on chemosensitivity of the panel of human cancer cell lines showed that there were large differences in sensitivity to gemcitabine and MTX among the five breast cancer cell lines (by factors of 1.00 Â 10 4 and 3.39 Â 10 3 for gemcitabine and MTX, respectively). As shown in Fig. 3 , comparison of drug sensitivities and expression levels of transporter proteins in the five cell lines showed high correlation coefficients (r) between sensitivity to gemcitabine and the expression levels of 4F2hc (r 5 0.781) and MRP5 (r 5 0.721) (Fig. 3, A and B) . However, despite showing the highest r value, 4F2hc was highly expressed only in the MCF-7 cell line, and levels in the other four cell lines were low (Fig. 3A) . In addition, it has been reported that 4F2hc itself lacks transport activity and forms heterodimers with other amino acid transporters such as LAT1 and xCT (Ganapathy et al., 2009) . Therefore, 4F2hc is likely to be indirectly involved in gemcitabine resistance.
Relatively high r values were also observed between sensitivity to MTX and expression levels of RFC1 (r 5 0.690) and ENT1 (r 5 0.566) (Fig. 3, C and D) . As shown in Fig. 3C , a high correlation of the protein expression level of RFC1 with sensitivity (|log 10 GI 50 |) to MTX (r 5 0.965) was observed for four breast cancer cell lines, excluding HBC-5. This result suggests that RFC1 plays a major role in MTX sensitivity in these cell lines (MCF-7, HBC-4, BSY-1, and MDA-MB-231), whereas some other mechanism is likely to be involved in HBC-5.
Involvement of MRP5 in Gemcitabine Transport and Sensitivity. Since protein expression level of MRP5 in the breast cancer cell lines was correlated to gemcitabine sensitivity (Fig. 3B) , the transport of gemcitabine by MRP5 was examined by vesicular uptake study using MRP5-expressing membrane vesicles. The vesicle-to-medium ratio of gemcitabine in MRP5-expressing vesicles was not significantly different from that of mock vesicles after a 10-minute incubation (Fig. 4A) . On the other hand, the vesicle-tomedium ratio of MTX, which is known to be a substrate of MRP5 (Wielinga et al., 2005) , in MRP5-expressing vesicles was significantly greater (3.36-fold) than that of mock vesicles after a 3-minute incubation (Fig. 4B) . This result suggests that gemcitabine is not a substrate of MRP5, though we cannot rule out the possibility that MRP5-mediated transport of other compounds may influence gemcitabine sensitivity.
Involvement of RFC1 in Methotrexate Sensitivity in Human Breast Cancer Cell Lines. The involvement of RFC1 in MTX sensitivity was examined by cellular uptake study of (Fig. 5) . Furthermore, the C/M ratio of [ 3 H]MTX at 48 hours' incubation was directly correlated with the expression level of RFC1 and sensitivity to MTX (r 5 0.982 and r 5 0.919, respectively, excluding HBC-5) (Fig. 6) . The HBC-5 cell line showed a relatively high C/M ratio of [ 3 H]MTX (202 ml/mg protein), even though it was resistant to MTX.
Protein Expression Levels of MTX-Metabolizing Enzymes in Human Breast Cancer Cell Lines. Since the MTX resistance of the HBC-5 cell line could not be explained in terms of transporter protein expression, we considered that MTX metabolism might be involved. Therefore, protein expression amounts of three MTX-metabolizing enzymes, dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS), and g-glutamyl hydrolase (GGH), were quantified in whole-cell lysate of MTX-sensitive HBC-4 and MTX-resistant HBC-5, since the expression level of RFC1 and uptake amount of [ 3 H]MTX at 48 hours were similar in the two cell lines. Protein expression of DHFR and GGH was detected in both cell lines, but there was no significant difference in their expression levels between the two cell lines (Table 5 ). The protein expression of FPGS was under the limit of quantification in both cell lines. To reduce the background noise in QTAP analysis, whole-cell lysates of these cell lines were separated by SDS-PAGE and in-gel-digested with trypsin. As a result of in-gel digestion, expression of FPGS was detected in both cell lines (Table 5 ). The expression level of FPGS in MTX-sensitive HBC-4 was 2.38-fold greater than that in MTX-resistant HBC-5.
Intracellular Amounts of MTX and MTX Polyglutamates in Human Breast Cancer Cell Lines. FPGS conjugates glutamate to MTX, producing MTX polyglutamates (MTX-Glu n ) in the cells. Therefore, the C/M ratios of MTX and MTX polyglutamates (MTX-Glu 2 ∼ MTX-Glu 7 ) after incubation with MTX for 24 hours were measured. MTX and MTX polyglutamates (MTX-Glu 2 ∼ MTX-Glu 5 ) were detected in both HBC-4 and HBC-5 cell lines, whereas MTX-Glu 6 was detected only in HBC-4 (Fig. 7A) . MTX-Glu 7 was under the limit of quantification in both cell lines. The C/M ratio of MTX in MTX-resistant HBC-5 was 2.01-fold greater than that in MTX-sensitive HBC-4, whereas the C/M ratios of MTXGlu 4 ∼ MTX-Glu 6 were greater in HBC-4 (Fig. 7B) .
Discussion
This is the first study to determine the absolute expression levels of multiple transporter proteins in membrane fraction of human stomach and breast cancer cell lines to identify key transporters involved in drug sensitivity. Among 90 membrane proteins examined, only GLUT1 and 4F2hc were present at quantifiable levels in all 11 cell lines, and RFC1 was quantifiable in 9 cell lines (Tables 1 and 2 ), indicating that protein expression levels vary widely from cell line to cell line, not only for xenobiotic transporters but also for amino acid or nucleoside transporters. ENT1 was detected in all five breast cancer cell lines but only one out of six stomach cancer cell lines. In contrast, MCT1 was not detected in breast cancer cell lines, but was detected in three stomach cancer cell lines. Previous studies have found greater ENT1 mRNA expression in breast cancer than in cancer cell lines derived from stomach cancer (Lu et al., 2002; Kameyama et al., 2011) . Immunohistochemical analysis showed that the frequency of MCT1 expression was greater in human stomach cancer tissues than in breast cancer tissues (Pinheiro et al., 2009 (Pinheiro et al., , 2010 . These transporter expression profiles are consistent with the present results.
MDR1 is an important ABC transporter involved in drug resistance of cancer cells. However, none of the cell lines expressed MDR1 at a sufficiently high level for quantification, though other ABC transporters, such as MRP1, MRP5, and BCRP, were detected (Tables 1-3) . Li et al. (2004) reported that MDR1 was highly expressed in a doxorubicin-resistant HepG2 cell line compared with the parental cell line. Abolhoda et al. (1999) also reported that MDR1 mRNA was increased after administration of doxorubicin in patients with unresectable sarcoma pulmonary metastases. Thus, MDR1 was proposed to play an important role in acquisition of resistance to anticancer drugs by chemotherapy. Indeed, the human cancer cell lines used in this study had not acquired resistance via drug exposure.
As shown in Fig. 1 , the protein expression level of MRP1 in membrane fraction was inversely correlated with sensitivity to five anticancer drugs in the three stomach cancer cell lines expressing MRP1. These five drugs were all reported to be substrates for MRP1 (Loscher and Potschka, 2005; Szakacs et al., 2006) . Therefore, it seems likely that these anticancer drugs were pumped out from cells by MRP1 in these cell lines. The sensitivity to etoposide was highly correlated with MRP1 expression level, and sensitivity to etoposide was increased when MRP1 transport activity was inhibited with MK571 ( Fig. 1 ; Table 4 ). Although MK571 was reported to inhibit transport mediated by MRP4 and MRP5, as well as MRP1 (Reid et al., 2003) , the present QTAP analysis showed that only MRP1 among the MK571-inhibited transporter proteins was expressed in these three stomach cancer cell lines (St-4, MKN45, and MKN1), suggesting that MK571 mainly inhibited efflux of etoposide mediated by MRP1. In addition, the intracellular amount of etoposide was increased when MRP1 transport activity was inhibited in these cell lines ( Fig. 2A) . This result suggested that an increase of intracellular etoposide concentration accounts for the increase of sensitivity to etoposide under conditions of MRP1 inhibition (Table 4) . Furthermore, the value of 1/(C/M ss Fig. 3 . Correlation between anticancer drug sensitivity and protein expression level in five human breast cancer cell lines. Chemosensitivity to gemcitabine (A and B) and MTX (C and D) was obtained from a database of chemosensitivities of a panel of human cancer cell lines (Nakatsu et al., 2005) . Dots and bars on the y-axis represent the mean 6 S.E.M. (n = 3). Membrane vesicles (10 mg) prepared from MRP5-transfected (MRP5) or parental vector-transfected (Mock) HEK293 cells were incubated at 37°C for 10 minutes (for gemcitabine) (A) or 3 minutes (for MTX, a known substrate for MRP5) (B) in the uptake medium containing 100 mM gemcitabine or 10 mM MTX in the presence of 4 mM ATP. The uptake amount of gemcitabine or MTX was measured by UPLC-MS-MS and expressed as vesicle-to-medium ratio (microliters per milligram of protein). Columns and bars represent the mean 6 S.E.M. (n = 4). *P , 0.05. ratio) 2 1/(C/M ss ratio MK571 ) is proportional to MK571-sensitive efflux clearance, as described in Materials and Methods. As shown in Fig. 2B , the expression level of MRP1 was correlated with the 1/(C/M ss ratio) 2 1/(C/M ss ratio MK571 ) value. Therefore, it appears that the expression level of MRP1 regulates etoposide efflux clearance in the cells. It has been reported that MRP1-transfected HEK293 cells showed increased resistance to etoposide compared with the parental cells (Nunoya et al., 2003) . Furthermore, T98G glioblastoma cells treated with tacrolimus, which decreases MRP1 expression, were reported to show increased sensitivity to etoposide (Garrido et al., 2011) . These previous studies suggested the involvement of MRP1 in etoposide resistance but did not determine the intracellular amount of etoposide. Our results indicate that a decrease of intracellular etoposide concentration owing to MRP1-mediated efflux of etoposide is involved in etoposide resistance of stomach cancer cell lines.
The present comparison between protein expression level and drug sensitivity suggested that the mechanism of drug sensitivity involves the target transporters in some of the cell lines, but not in others. In the case of MRP1 expression and etoposide sensitivity shown in Fig. 1A , three cell lines (St-4, MKN45, and MKN1) showed a good correlation, suggesting that they share a drug sensitivity mechanism involving MRP1. However, the other three lines (MKN28, MKN7, and MKN74) did not exhibit such a correlation, and mechanisms not involving MRP1 presumably influence the etoposide sensitivity. These three cell lines expressed GLUT1 at higher levels and were less sensitive to etoposide than the three MRP1-expressing cell lines. Overall survival of patients with high-GLUT1-expressing stomach cancer was reported to be shorter than that of patients with lower GLUT1 expression (Kawamura et al., 2001) . Thus, high expression of GLUT1 could be involved in another mechanism of etoposide (Nakatsu et al., 2005) . Each dot on the y-axis represents the mean (n = 4). (Nakatsu et al., 2005) . Each dot on the y-axis represents the mean (n = 4).
resistance associated with increased malignancy of stomach cancer cell lines.
In the case of RFC1 expression and MTX sensitivity shown in Fig. 3C , four cell lines (MCF-7, HBC-4, BSY-1, and MDA-MB-231) were suggested to share the drug sensitivity mechanism involving RFC1. RFC1 is an influx transporter of folate and also accepts MTX as a substrate (Sharif et al., 1998) . The present study is the first to demonstrate a correlation of protein expression level of RFC1 with MTX sensitivity and intracellular amount of [ 3 H]MTX. RFC1-mediated uptake of MTX is expected to be increased in breast cancer cell lines with increased RFC1 expression, resulting in increased sensitivity to MTX.
In contrast, HBC-5 was not on the correlation line of the four cell lines, suggesting that some other mechanism(s) predominantly influences MTX sensitivity in HBC-5. BCRP was detected in only HBC-5 among the 11 cancer cell lines. BCRP belongs to the ABCG family and was reported to mediate efflux transport of MTX from cells (Chen et al., 2003; Volk and Schneider, 2003) . Therefore, BCRP is likely to be involved in the MTX resistance of HBC-5. However, the MTX level in HBC-5 was greater than that in HBC-4 after exposure to MTX for 48 hours, even though HBC-5 was more resistant than HBC-4. This result indicates that differences in transmembrane transport of MTX mediated by transporters cannot explain the difference in MTX sensitivity between HBC-5 and HBC-4.
Glutamate residues are added to MTX in cells, and efflux of MTX polyglutamates from the cells is slow, resulting in prolonged retention and enhanced efficacy of MTX (Cole et al., 2001) . Decreased intracellular levels of MTX polyglutamates were reported to be involved in MTX resistance (Waltham et al., 1997; Assaraf, 2007) . This polyglutamylation process is dependent on both FPGS, which adds glutamate residues to MTX, and GGH, which removes glutamate residues (Waltham et al., 1997) . It was also reported that overexpression of DHFR, which is the target enzyme of MTX, was involved in MTX resistance (Gorlick et al., 1996) . In HBC-5, the expression level of FPGS was only 42.1% relative to that in HBC-4, whereas the levels of GGH and DHFR were not significantly different (Table 5) . Furthermore, the amounts of MTX with longer glutamate chains (MTX-Glu 4 , -Glu 5 , and -Glu 6 ) were less in HBC-5 than in HBC-4 (Fig. 7) . Taking these results into consideration, the difference of FPGS protein expression was considered to be involved in the difference in MTX sensitivity between HBC-5 and HBC-4. However, the difference in intracellular level of even MTXGlu 6 , the longest detected glutamate chain, was 2.09-fold (HBC-4: 199 fmol/mg protein; HBC-5: under the limit of quantification of ,95.1 fmol/mg protein), whereas HBC-5 was 1.29 Â 10 3 times more resistant to MTX as compared with HBC-4. Therefore, the difference in FPGS expression may not fully explain the difference in MTX resistance. The DHFRinhibitory activities of individual MTX polyglutamates are unknown and should be clarified in a future analysis. Furthermore, an effect of mutation in DHFR cannot be ruled out, because mutation of leucine-22 to arginine in DHFR   TABLE 5 Expression levels of metabolic enzymes of methotrexate (MTX) in wholecell lysate of MTX-resistant and -sensitive human breast cancer cell lines Whole-cell lysates of two human breast cancer cell lines (HBC-4 and HBC-5) were digested with trypsin. Proteins of whole-cell lysate for in-gel trypsin digestion were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the gel bands (50-75 kDa) were cut out for in-gel trypsin digestion. Tryptic digest of each cell line was analyzed by multiplexed selected reaction monitoring/multiple reaction monitoring (SRM/MRM) with liquid chromatography-linked tandem mass spectrometry. The amount of each protein was determined as the average of 5 to 12 quantitative values from four SRM/MRM transitions in two or four analyses. Each value represents the mean 6 S.E.M. (n = 5-12 SRM/MRM transitions). U.L.Q. means "under the limit of quantification," and the value in brackets following U.L.Q. represents the value of the quantification limit (fmol/mg protein). Key Transporters for Etoposide and Methotrexate Sensitivity lowered the affinity for MTX and was reported to be involved in MTX resistance (Lewis et al., 1995) .
Enzyme
Our results indicate that a decreased intracellular concentration of etoposide owing to higher expression of MRP1 results in etoposide resistance in human stomach cancer cell lines. In human breast cancer cell lines, a decreased intracellular concentration of MTX owing to lower expression of RFC1 appeared to be involved in MTX resistance, together with decreased concentrations of intracellular MTX polyglutamates, owing to lower expression of FPGS. Moreover, the present correlation analysis indicates that multiple proteins are candidates for involvement in anticancer drug resistance. GLUT1 was suggested to be involved in etoposide resistance in stomach cancer cell lines, and MRP5 and 4F2hc were suggested to be involved in gemcitabine sensitivity in breast cancer cell lines. These findings suggest that absolute quantification of multiple membrane proteins by means of QTAP could be a useful strategy for identification of candidate proteins involved in drug sensitivity in other cases.
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